Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...

Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

By Ludwig Burger FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing its multiple ...

The company is evaluating the use of fully human intranasal anti-CD3 monoclonal antibody foralumab for the treatment of patients with Secondary Progressive Multiple Sclerosis in a phase 2a study. The ...

In a new study, researchers found that increased expression of gene PRDM1-S triggers loss of immune regulation in autoimmune conditions like multiple sclerosis (MS). The findings could pave the way ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Progentos' CEO is also the co ...

(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a ...

Multiple sclerosis (MS) is recognized as one of the most prevalent neurological diseases among young adults, with symptoms typically emerging between ages 20 to 40 years. The condition is ...

FRANKFURT, Jan 13 (Reuters) - Merck KGaA said on Tuesday it had bought the rights to develop and market an experimental multiple sclerosis (MS) drug from British biotech company Apitope, expanding its ...

Exposure to multiple sclerosis (MS) monoclonal antibody treatment during breastfeeding appeared to have no negative effect on the early development or health of infants, registry data in Germany ...